Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S's Ozempic and Wegovy in key markets as patents on the blockbuster weight-loss drugs expire next year. The ...

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...

Biocon Biologics established its first North American headquarters right here in the great Garden State, selecting Bridgewater as the site. The global biosimilars company announced the location this ...

Biocon Ltd, Asia's premier biotechnology company, announced that the Board of Directors of the Company, in their meeting today, have approved the induction of Dr Arun Chandavarkar, on to the board of ...

In a move aimed at expanding affordable treatment options for millions of Americans living with diabetes, Biocon Biologics Ltd. and nonprofit generic drug manufacturer Civica, Inc. have announced a ...

Biocon Ltd announced that its subsidiary Biocon Biologics Ltd (BBL), announced that Yesafili (aflibercept) is now publicly funded in Ontario, Canada, for the treatment of retinal diseases. It is a ...

Biocon Ltd said on September 4 that the US FDA has completed a routine inspection of its Biocon Biologics facility in Bengaluru. The inspection, held between August 26 and September 3, covered drug ...

Biocon Ltd will integrate Biocon Biologics Ltd as a wholly owned subsidiary in a deal valuing the unit at $5.5 billion, the company said on Saturday. Biocon will acquire the remaining stake in Biocon ...